drugset
drugset / Trial / NCT06634797

A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age

NCT06634797 ↗

Phase 4 Completed 1000 enrolled ModernaTX, Inc.
RandomizedCrossoverTriple-blindBasic science

Summary

The primary objective of this study is to assess cardiac troponin I (cTnI) values in participants who received mRNA-1273.712 or placebo.

Timeline

Start
2024-10-08
Primary completion
2025-01-20
Completion
2025-01-20

Drugs

EvaluationDrugModalityDoseRoute
Subject mRNA-1273.712 Messenger RNA (mRNA) — Intramuscular

Indications

No indication recorded.